Founded in 2018, Chicago-based Sibel Health offers the ANNE® platform, a suite of FDA-cleared wearable sensors integrated with mobile software, cloud analytics, and AI-driven algorithms to capture continuous, real-world vital-sign data. The system is already paired with Samsung mobile devices for waveform display and alerting and is used by leading pharmaceutical companies through the Discovery platform to collect home-based data for clinical trials. Sibel aims to move healthcare from episodic, reactive monitoring to continuous, predictive clinical intelligence. Recent strategic collaborations with Maruho focus on dermatology-related digital therapeutics, starting with an itch-monitoring application. The company maintains an international presence with an office in Seoul and touts a mission of delivering “Better Health Data for All®.” Financially, Sibel has brought its total Series C funding to $39 million, supported by a mix of healthcare, strategic, and technology investors. Two new board appointments—Kimberly Querrey as Chairwoman and Tim Sullivan as an independent director—add governance and healthcare commercialization expertise to guide upcoming growth.

Total raised

$102M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2025